Strategic Acquisition Fit There is potential sales opportunity through engaging Sona Nanotech post-acquisition to position Targeted Hyperthermia as an adjunct or alternative cancer therapy, leveraging shared nanorod and photothermal platform capabilities.

Early Stage Validation Targeted Hyperthermia has demonstrated concept validity and collaboration history with SomaLogic, suggesting a receptive base for pilot studies or grant-funded partnerships with researchers and hospitals seeking innovative, less invasive cancer treatments.

Cost Competitiveness Position the therapy as a cost-competitive option relative to surgery, chemotherapy, and radiation, creating a compelling value proposition for payers and hospital networks aiming to reduce total treatment costs.

Safety and Efficacy Focus Emphasize the safety profile and selective tumor targeting to appeal to oncology centers prioritizing patient safety and reduced adverse events, which can accelerate adoption in clinical workflows.

Strategic Partnerships Leverage past collaborations with NanoHybrids and UCIA-affiliated initiatives to pursue co-development, manufacturing, and distribution partnerships, expanding reach into research institutions and regional markets.